Advancement in Treating Uncommon EGFR Mutations: Key Takeaways
Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.
Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight
Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.
UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations
Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC
Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Optimizing Afatinib Use: Dosing Strategies and Adverse Event Management
Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.
Treatment Strategies for Uncommon EGFR Mutations in NSCLC
Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.
Navigating Uncommon EGFR Mutations in NSCLC: Challenges and Insights
Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.
Standard-of-Care Approaches in EGFR-Mutant NSCLC
Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.
Navigating Uncommon Mutations in NSCLC Treatment Decisions
The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.
Non–Small Cell Lung Cancer: Streamlining Turnaround Times in Biomarker Testing
Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.
Available Methods for Biomarker Testing in Non–Small Cell Lung Cancer
Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.
Strategic Approaches to Biomarker Testing in NSCLC: Optimal Timing
Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.
Advancement in NSCLC Precision Medicine: Biomarker Testing
Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.
Dr. Seetharamu on Utilizing a Patient-Centered Treatment Approach in Lung Cancer
Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.
Dr. Seetharamu on Immunotherapy Treatment for Head and Neck Cancers
Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512